ESR2 and ovarian cancer: Recent studies have shown that natural ERβ agonists have the potential to significantly inhibit the growth of ovarian-cancer cells through anti-inflammatory and proapoptotic effects, and can be used as novel therapeutic agents for the treatment of ovarian cancer [66].